How long can you stay on vaginal estrogen?
There is no fixed stop date for vaginal estrogen. Because genitourinary syndrome of menopause (GSM) is chronic and progressive, low-dose vaginal estrogen works as ongoing therapy rather than a short course, and symptoms tend to return once you stop. Most women stay on it long term, using it as long as the symptoms would otherwise bother them, with periodic follow-up to check that it is still working for you.
Think of it the way you would think of treating any long-standing condition. The underlying cause, low estrogen in the tissues after menopause, does not go away on its own, so the treatment is meant to continue for as long as you want relief. There is no built-in end point after which you are supposed to stop, and no maximum number of years after which it becomes unsafe.
Why it is not a short course
GSM is chronic and progressive and is unlikely to resolve without treatment. Vaginal estrogen treats the symptoms, not the menopause behind them, so when the estrogen is withdrawn the tissue changes and the symptoms generally come back. In studies, symptom relief typically takes one to three months to build, and continued therapy is generally required because symptoms recur when treatment stops.
What the safety evidence actually shows
Formal clinical-trial safety data for low-dose vaginal estrogen generally run to about one year, and endometrial safety in particular has not been studied in trials beyond a year. Longer than that, we are relying on observational data rather than randomized trials. Those longer-term observations have not shown evidence of harm with extended use. So the fair summary is that the controlled trials are short, and the real-world experience over longer periods has been reassuring rather than alarming.
Low-dose vaginal estrogen is a local treatment. Systemic absorption is minimal, and blood estrogen levels stay in the normal postmenopausal range. Because of that, women at average risk do not need to add a progestogen to protect the uterus, and they do not need routine endometrial monitoring simply because they are using it. The AUA, SUFU, and AUGS guideline is explicit that endometrial surveillance should not be performed solely because someone uses local low-dose vaginal estrogen, and that this treatment does not raise the risk of endometrial hyperplasia with atypia or endometrial cancer. The same guideline notes that long-term treatment and follow-up may be needed to keep symptoms controlled, which in practice means staying in touch with your clinician rather than stopping on a schedule.
New bleeding is always checked
None of that changes how new bleeding is handled. Any new bleeding after menopause is evaluated in its own right, no matter how long you have been using vaginal estrogen, because vaginal estrogen should not be used when there is undiagnosed bleeding, and any bleeding during treatment calls for an evaluation with your doctor.
How I approach it
I typically recommend that when patients start topical vaginal estrogen, they plan on continuing it for life. If you ever want to take a break or stop, that is a reasonable thing to try. The main thing to expect is that the symptoms tend to come back, and if they do, restarting is a normal and reasonable next step. Nothing about stopping and later resuming makes the treatment less safe or less effective.
References
- Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clinic Proceedings. 2017. doi:10.1016/j.mayocp.2017.08.019
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Kaufman MR, Ackerman AL, Amin KA, et al. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline. American Urological Association. 2025.
← Learn more about Vaginal Estrogen